SEC Filings

SEC Filings

Filing date	Description	Form	View
Sep 28, 2023	CORRESP	CORRESP	View HTML 0001104659-23-104570.pdf 0001104659-23-104570.rtf 0001104659-23-104570.xls
Sep 27, 2023	Amended Registration statement for face-amount certificate companies	S-1/A	View HTML 0001104659-23-104363.pdf 0001104659-23-104363.rtf 0001104659-23-104363.xls
Sep 22, 2023	Report of unscheduled material events or corporate event	8-K	View HTML 0001104659-23-103175.pdf 0001104659-23-103175.rtf 0001104659-23-103175.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
Sep 12, 2023	Amended Registration statement for face-amount certificate companies	S-1/A	View HTML 0001104659-23-099802.pdf 0001104659-23-099802.rtf 0001104659-23-099802.xls
Aug 30, 2023	UPLOAD	UPLOAD	View HTML 0000000000-23-009601.pdf 0000000000-23-009601.rtf
Aug 25, 2023	Registration statement for face-amount certificate companies	S-1	View HTML 0001104659-23-095377.pdf 0001104659-23-095377.rtf 0001104659-23-095377.xls
Aug 07, 2023	Report of unscheduled material events or corporate event	8-K	View HTML 0001558370-23-013626.pdf 0001558370-23-013626.rtf 0001558370-23-013626.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
Aug 07, 2023	Quarterly report which provides a continuing view of a company's financial position	10-Q	View HTML 0001558370-23-013645.pdf 0001558370-23-013645.rtf 0001558370-23-013645.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
Jul 19, 2023	Statement of changes in beneficial ownership of securities	4	View HTML 0001235802-23-000077.pdf 0001235802-23-000077.rtf 0001235802-23-000077.xls
Jul 06, 2023	Statement of changes in beneficial ownership of securities	4	View HTML 0001235802-23-000075.pdf 0001235802-23-000075.rtf 0001235802-23-000075.xls

Data provided by Kaleidoscope.

For investor inquiries, please contact:

ReShape Lifesciences Investor Contact:
Thomas Stankovich
Chief Financial Officer
949-276-6042
ir@ReShapeLifesci.com

Investor Contacts:
Rx Communications Group
Michael Miller
917-633-6086
mmiller@rxir.com

PRINT PAGE

EMAIL PAGE